EGFR and breast carcinoma: The above clinical findings are confirmed by several in vitro studies which show that continuous culturing of the human breast cancer cell line MCF7 in the presence of the anti- estrogen tamoxifen or fulvestrant increases EGFR and ERBB2 expression and the activation of downstream signalling kinases (e.g. MAPK) [9-11].